Search

Your search keyword '"Alsifri, Saud"' showing total 21 results
Start Over Author "Alsifri, Saud"
21 results on '"Alsifri, Saud"'

1. Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study

Author

Alsheikh, Abdulrahman, Alshehri, Ali, Alzahrani, Saad, Jammah, Anwar A., Alqahtani, Fahad, Alotaibi, Metib, Aldahash, Raed, Alhozali, Amani M., Alsabaan, Fahad, Almehthel, Mohammed, Aljuhani, Naser, Aldabeis, Ali, Alamri, Moneer, Maghawry, Waleed, Alzaman, Naweed, Alshaikh, Alshaima, M. Alnozha, Omar, Issak, Emad R., and Alsifri, Saud

Published
2024
Full Text
View/download PDF

5. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes

Author

Khunti, Kamlesh, Alsifri, Saud, Aronson, Ronnie, Cigrovski Berković, Maja, Enters-Weijnen, Catherine, Forsén, Tom, Galstyan, Gagik, Geelhoed-Duijvestijn, Petronella, Goldfracht, Margalit, Gydesen, Helge, Kapur, Rahul, Lalic, Nebojsa, Ludvik, Bernhard, Moberg, Erik, Pedersen-Bjergaard, Ulrik, and Ramachandran, Ambady

Published
2017
Full Text
View/download PDF

6. Saudi Consensus on the Usage of Sodium-Glucose Cotransporter-2 Inhibitors on the Management of Chronic Kidney Diseases

Author

Alsheikh, Abdulrahman, primary, Aljedai, Ahmed, additional, Almudaiheem, Hajer, additional, Alaidarous, Salwa, additional, Alshehri, Ali, additional, Elbadawi, Hussein, additional, Alghamdi, Saeed, additional, Aljohani, Faisal, additional, Alobaidi, Sami, additional, Altuwaijri, Talal A., additional, Almatham, Khalid, additional, Strain, David, additional, Evans, Marc, additional, Issak, Emad R., additional, and Alsifri, Saud, additional

Published
2023
Full Text
View/download PDF

7. Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report

Author

Alromaih, Ali, primary, Alshamrani, Abdullah, additional, Alharbi, Bandar, additional, Alharbi, Ibtissam, additional, Alharbi, Turki, additional, Bokhari, Samia, additional, Elbadawi, Hussein, additional, Almehthel, Mohammed, additional, Alsaeed, Abdulghani, additional, Alyahia, Khalid, additional, Alhowyan, Fatimah, additional, Evans, Marc, additional, Mehta, Roopa, additional, Issak, Emad, additional, and Alsifri, Saud, additional

Published
2023
Full Text
View/download PDF

11. Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report

Author

Alsifri, Saud, primary, Elbadawi, Hussein, additional, Alsabaan, Fahad, additional, Almahfouz, Abdulraouf, additional, Alyahya, Khalid, additional, Shesha, Eman, additional, Esba, Laila Abu, additional, Alnais, Meshal, additional, Aldahash, Raed, additional, Alharbi, Turky, additional, Aljaser, Saleh, additional, and Issak, Emad R., additional

Published
2022
Full Text
View/download PDF

14. Clinical Practice Guideline for the Management of Overweight and Obesity in Adults in Saudi Arabia

Author

Alshaikh, Abdulrahman, primary, Aljedai, Ahmed, additional, Alfadda, Assim, additional, Alrobayan, Abdulrahman, additional, Bawahab, Abdulwahab, additional, Ouf, Shaza Abou, additional, Sultan, Ali, additional, Alhozali, Amani, additional, Bawazeer, Mohammed, additional, Sheshah, Eman, additional, Alqahtani, Fahad, additional, Mosli, Hala, additional, Elbadawi, Hussein, additional, Alamri, Khaled, additional, Alshali, Khalid, additional, Aldawish, Mohammed, additional, Alsofiani, Mohammed, additional, Aldahash, Raed, additional, Alfawaz, Rasha, additional, Alamoudi, Reem, additional, Jamal, Wessam, additional, Almudaiheem, Hajer, additional, Issak, Emad R., additional, and Alsifri, Saud, additional

Published
2022
Full Text
View/download PDF

16. Saudi Consensus for Low-Premixed Insulin Analogues in Type 2 Diabetes: Consensus Report

Author

Alshaikh, Abdulrahman, primary, Aljamal, Mohammed, additional, Alsifri, Saud, additional, Alrumaih, Ali, additional, Bokhari, Samia, additional, Almuzaini, Mohammed, additional, Alyahya, Khalid, additional, Shaikh, Abdulaziz Bin, additional, Alharbi, Turky, additional, Aljuwair, Rashid, additional, Alsabaan, Fahad, additional, and Issak, Emad R., additional

Published
2021
Full Text
View/download PDF

19. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies

Author

Pedersen‐Bjergaard, Ulrik, primary, Alsifri, Saud, additional, Aronson, Ronnie, additional, Berković, Maja Cigrovski, additional, Galstyan, Gagik, additional, Gydesen, Helge, additional, Lekdorf, Jesper Barner, additional, Ludvik, Bernhard, additional, Moberg, Erik, additional, Ramachandran, Ambady, additional, and Khunti, Kamlesh, additional

Published
2018
Full Text
View/download PDF

20. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes

Author

Khunti, Kamlesh, Alsifri, Saud, Aronson, Ronnie, Berkovic, Maja Cigrovski, Enters-Weijnen, Catherine, Forsen, Tom, Galstyan, Gagik, Geelhoed-Duijvestijn, Petronella, Goldfracht, Margalit, Gydesen, Helge, Kapur, Rahul, Lalic, Nebojsa, Ludvik, Bernhard, Moberg, Erik, Pedersen-Bjergaard, Ulrik, Ramachandran, Ambady, HAT Investigator Grp, Clinicum, Department of General Practice and Primary Health Care, and University of Helsinki

Subjects
Male, Pediatrics, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, DOSING IRREGULARITIES, Type 2 diabetes, 0302 clinical medicine, Endocrinology, PHYSICIANS, Quality of life, QUALITY-OF-LIFE, Surveys and Questionnaires, Insulin, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, PREDICTORS, Observational, Diabetes, 1. No poverty, Global, General Medicine, Fear, Middle Aged, WORK PRODUCTIVITY, 3. Good health, Insulin/adverse effects, Europe, Cohort, Female, Adult, medicine.medical_specialty, Canada, HAT study, Hypoglycaemia, 030209 endocrinology & metabolism, Hypoglycemic Agents/therapeutic use, Hypoglycemia, Hypoglycemia/chemically induced, FREQUENCY, EVENTS, 03 medical and health sciences, Patient Education as Topic, Diabetes mellitus, Internal Medicine, medicine, MANAGEMENT, Humans, Hypoglycemic Agents, COHORT, Patient Reported Outcome Measures, Type 1 diabetes, business.industry, Diabetes Mellitus, Type 2/complications, Self-Management, CARE, medicine.disease, Surgery, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, 3121 General medicine, internal medicine and other clinical medicine, Diabetes Mellitus, Type 1/complications, business
Abstract

Aims: Data on the impact of hypoglycaemia on patients' daily lives and diabetes self-management, particularly in developing countries, are lacking. The aim of this study was to assess fear of, and responses to, hypoglycaemia experienced by patients globally. Materials and methods: This non-interventional, multicentre, 4-week prospective study using self-assessment questionnaires and patient diaries consisted of 27,585 patients, >= 18 years, with type 1 diabetes (n = 8022) or type 2 diabetes (n = 19,563) treated with insulin for > 12 months, at 2004 sites in 24 countries worldwide. Results: Increased blood glucose monitoring (69.7%) and seeking medical assistance (62.0%) were the most common responses in the 4 weeks following hypoglycaemic events for patients with type 1 diabetes and type 2 diabetes, respectively. Approximately 44% of patients with type 1 diabetes or type 2 diabetes increased calorie intake in response to a hypoglycaemic episode. Following hypoglycaemia, 3.9% (type 1 diabetes) and 6.2% (type 2 diabetes) of patients took leave from work or study. Regional differences in fear of, and responses to, hypoglycaemia were evident - in particular, a lower level of hypoglycaemic fear and utilisation of healthcare resources in Northern Europe and Canada. Conclusions: Hypoglycaemia has a major impact on patients and their behaviour. These global data for the first time reveal regional variations in response to hypoglycaemia and highlight the importance of patient education and management strategies. (C) 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the

Published
2016

21. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies.

Author

Pedersen‐Bjergaard, Ulrik, Alsifri, Saud, Aronson, Ronnie, Berković, Maja Cigrovski, Galstyan, Gagik, Gydesen, Helge, Lekdorf, Jesper Barner, Ludvik, Bernhard, Moberg, Erik, Ramachandran, Ambady, and Khunti, Kamlesh

Subjects
*HYPOGLYCEMIA, *DIABETES, *CLINICAL trials, *INSULIN, *TYPE 2 diabetes
Abstract

Aims: Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in real‐world clinical practice. Current data on hypoglycaemia are generally limited to those reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT) study, a non‐interventional real‐world study of hypoglycaemia, assessed hypoglycaemia in 27 585 individuals across 24 countries. The present study compared the incidence of hypoglycaemia from the HAT study with other similarly designed, large, real‐world studies. Materials and Methods: A literature search of PubMed (1995‐2017) for population‐based studies of insulin‐treated patients with type 1 or type 2 diabetes (T1D, T2D), excluding clinical trials and reviews, identified comparable population‐based studies reporting the incidence of hypoglycaemia. Results: The 24 comparative studies, including more than 24 000 participants with T1D and more than 160 000 participants with T2D, varied in design, size, inclusion criteria, definitions of hypoglycaemia and method of recording hypoglycaemia. Reported rates (events per patient‐year [PPY]) of hypoglycaemia were higher in patients with T1D than in those with T2D (overall T1D, 21.8‐73.3 and T2D, 1.3‐37.7; mild/non‐severe T1D, 29.0‐126.7 and T2D, 1.3‐41.5; severe T1D, 0.7‐5.8 and T2D, 0.0‐2.5; nocturnal T1D, 2.6‐11.3 and T2D, 0.38‐9.7) and were similar to the ranges found in the HAT study. Conclusions: The HAT data on hypoglycaemia incidence were comparable with those from other real‐world studies and indicate a high incidence of hypoglycaemia among insulin‐treated patients. Differences in rates among studies are mostly explained by differences in patient populations and study methodology. The goal of reducing hypoglycaemia should be a target for continued educational and evidence‐based pharmacological interventions. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results